Chermont Sérgio, Quintão Mónica M P, Mesquita Evandro T, Rocha Nazareth N, Nóbrega Antonio Claudio L
Post-Graduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, Brazil.
J Cardiopulm Rehabil Prev. 2009 Jan-Feb;29(1):44-8. doi: 10.1097/HCR.0b013e3181927858.
Noninvasive ventilation with continuous positive airway pressure (CPAP) has been used in patients with chronic heart failure (CHF), although its effect on exercise tolerance in these patients is unknown. The aim of this study was to determine the effects of CPAP on exercise tolerance in outpatients with CHF.
Following a double-blind, randomized, crossover, and placebo-controlled protocol, 12 patients with CHF (8 male; 4 female; age 54 +/- 12 years; body mass index 27.3 +/- 1.8 kg/m2, New York Heart Association Class II, III) underwent CPAP via nasal mask for 30 minutes in a recumbent position. Mask pressure was 3 cm H2O for 10 minutes, followed by individual progression up to 4 to 6 cm H2O, whereas placebo was fixed 0 to 1 cm H2O. A 6-minute walk test was performed after placebo and CPAP.
Continuous positive airway pressure decreased the resting heart rate (pre: 80 +/- 17 bpm; post: 71 +/- 15 bpm; P = .001) and mean arterial pressure (pre: 103 +/- 14 mm Hg; post: 97 +/- 13 mm Hg; P = .008). During exercise test, CPAP increased the distance covered (CPAP: 538 +/- 78 m; placebo: 479 +/- 83 m; P < .001) and the peak heart rate (CPAP: 98 +/- 17; placebo: 89 +/- 12 bpm; P = .049) but did not change the peak mean arterial pressure (P = .161).
Noninvasive ventilation with CPAP increased exercise tolerance in patients with stable CHF. Future clinical trials should investigate whether this effect is associated with improved clinical outcome.
持续气道正压通气(CPAP)的无创通气已用于慢性心力衰竭(CHF)患者,但其对这些患者运动耐量的影响尚不清楚。本研究的目的是确定CPAP对CHF门诊患者运动耐量的影响。
按照双盲、随机、交叉和安慰剂对照方案,12例CHF患者(8例男性;4例女性;年龄54±12岁;体重指数27.3±1.8kg/m²,纽约心脏协会II、III级)通过鼻罩在卧位接受CPAP治疗30分钟。面罩压力在10分钟内为3cmH₂O,随后根据个体情况逐渐增加至4至6cmH₂O,而安慰剂固定为0至1cmH₂O。在安慰剂和CPAP治疗后进行6分钟步行试验。
持续气道正压通气降低了静息心率(治疗前:80±17次/分;治疗后:71±15次/分;P = .001)和平均动脉压(治疗前:103±14mmHg;治疗后:97±13mmHg;P = .008)。在运动试验期间,CPAP增加了行走距离(CPAP:538±78m;安慰剂:479±83m;P < .001)和峰值心率(CPAP:98±17;安慰剂:89±12次/分;P = .049),但未改变峰值平均动脉压(P = .161)。
CPAP无创通气提高了稳定CHF患者的运动耐量。未来的临床试验应研究这种效果是否与改善临床结局相关。